Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Naunyn-Schmiedeberg's Archives of Pharmacology

• Publication date

  1991-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00174752PMID 1663589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclic nucleotide phosphodiesterases.

  2001cited by this paper
• Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors.

  1992cited by this paper
• Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.

  1991cited by this paper
• Zardaverine as a selective inhibitor of phosphodiesterase isozymes.

  1991cited by this paper
• Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.

  1991cited by this paper
• The involvement of extracellular calcium in the formation of 5-lipoxygenase metabolites by human polymorphonuclear leukocytes.

  1991cited by this paper
• Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle

  1990cited by this paper
• Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

  1990cited by this paper
• The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function

  1990cited by this paper
• Immunocytology on microwave-fixed cells reveals rapid and agonist-specific changes in subcellular accumulation patterns for cAMP or cGMP.

  1990cited by this paper
• Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.

  1990cited by this paper
• Involvement of calcium in the thimerosal-stimulated formation of leukotriene by fMLP in human polymorphonuclear leukocytes.

  1990cited by this paper
• Is phosphodiesterase inhibition a relevant bronchospasmolytic principle?

  1989cited by this paper
• The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides.

  1989cited by this paper
• Chemotactic peptide induces cAMP elevation in human neutrophils by amplification of the adenylate cyclase response to endogenously produced adenosine.

  1989cited by this paper
• Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.

  1989cited by this paper
• Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.

  1988cited by this paper
• The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response.

  1988cited by this paper
• Effects of phosphodiesterase inhibitors on normal and chemically‐skinned isolated airway smooth muscle

  1987cited by this paper
• The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

  1987cited by this paper
• Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma.

  1987cited by this paper
• Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin.

  1987cited by this paper
• Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes.

  1987cited by this paper
• The leukotriene B4 paradox: neutrophils can, but will not, respond to ligand-receptor interactions by forming leukotriene B4 or its omega-metabolites.

  1987cited by this paper
• Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

  1986cited by this paper
• Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors.

  1986cited by this paper
• Inhibitory effect of prostaglandin E2, forskolin, and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils.

  1986cited by this paper
• Characterization of cyclic-nucleotide phosphodiesterase activities in resting and N-formylmethionylleucylphenylalanine-stimulated human neutrophils.

  1986cited by this paper
• Calmodulin-dependency of human neutrophil phosphodiesterase

  1986cited by this paper
• A new generation of Ca2+ indicators with greatly improved fluorescence properties.

  1985cited by this paper
• Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils.

  1985cited by this paper
• Chemoattractant-elicited alterations of cAMP levels in human polymorphonuclear leukocytes require a Ca2+-dependent mechanism which is independent of transmembrane activation of adenylate cyclase.

  1985cited by this paper
• Proteolytic activation of calmodulin-dependent cyclic nucleotide phosphodiesterase.

  1985cited by this paper
• Evidence that the functional responses of human neutrophils occur independently of transient elevations in cyclic AMP levels.

  1983cited by this paper
• Increased levels of cyclic adenosine-3',5'-monophosphate in human polymorphonuclear leukocytes after surface stimulation.

  1980cited by this paper
• An improved assay of cyclic 3′,5′-nucleotide phosphodiesterases with QAE-Sephadex columns

  1980cited by this paper

• Inhibition of Recruitment and Activation of Neutrophils by Pyridazinone-Scaffold-Based Compounds

  2022cites this paper
• Where are we now, and where do we go from here?

  2019cites this paper
• Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease

  2018cites this paper
• PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.

  2016cites this paper
• Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis

  2016influential citation
• CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration

  2015cites this paper
• Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

  2015cites this paper
• Synthesis and reactive oxygen species scavenging activity of halogenated alkaloids from boldine

  2012influential citation
• Recent Contributions to Knowledge of the Mechanism of Action of Nimesulide

  2012cites this paper
• Phosphodiesterase inhibitors: history of pharmacology.

  2011cites this paper
• Perfil farmacológico del roflumilast

  2010cites this paper
• [Pharmacological profile of roflumilast].

  2010cites this paper
• Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis

  2010cites this paper
• Inhibition of HA Synthase 3 mRNA Expression, with a Phosphodiesterase 3 Inhibitor, Blocks Lung Injury in a Septic Ventilated Rat Model

  2009influential citation
• Effects of Phosphodiesterase 4 Inhibition on Alveolarization and Hyperoxia Toxicity in Newborn Rats

  2008cites this paper
• Inhaled milrinone attenuates experimental acute lung injury

  2008cites this paper
• A benzodiazepines derived compound, 4-(3-chlorophenyl)-1,3-dihydronaphtho [2,3-b][1,4]diazepin-2-one (ND700C), inhibits fMLP-induced superoxide anion release by activating protein phosphatase 2A in human neutrophils.

  2008influential citation
• Correlations of PDE-4 inhibition between enzymes of smooth muscle and inflammatory cell sources

  2007cites this paper
• The effects of the Pseudomonas aeruginosa-derived pigment, 1-hydroxyphenazine, on calcium metabolism and release of primary granule enzymes from activated human neutrophils in vitro

  2007cites this paper
• Steady-State Pharmacokinetics of Roflumilast and Roflumilast N-Oxide in Patients with Mild and Moderate Liver Cirrhosis

  2007cites this paper
• Inhibition of superoxide anion and elastase release in human neutrophils by 3′‐isopropoxychalcone via a cAMP‐dependent pathway

  2006cites this paper
• Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway.

  2006cites this paper
• Inhibitory Effect of KBT-3022, a New Anti-platelet Agent, on Infiltration of Polymorphonuclear Leukocytes Induced by Leukotriene B4 or Formyl-Methionyl-Leucyl-Phenylalanine in Mice

  2006cites this paper
• Suppression of respiratory burst in human neutrophils by new synthetic pyrrolo-benzylisoquinolines.

  2005cites this paper
• PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.

  2005cites this paper
• The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide

  2005cites this paper
• The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.

  2005cites this paper
• Histamine‐induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP

  2004cites this paper
• The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys

  2004cites this paper
• Reactive oxygen species (ROS) generation inhibited by aporphine and phenanthrene alkaloids semi-synthesized from natural boldine.

  2004cites this paper
• Selective Phosphodiesterase Inhibitors in the Treatment of Respiratory Disease

  2004cites this paper
• In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood.

  2003cites this paper
• Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure

  2003influential citation
• Investigation of the cellular mechanism of inhibition of formyl-methionyl-leucyl-phenylalanine-induced superoxide anion generation in rat neutrophils by 2-benzyloxybenzaldehyde.

  2003cites this paper
• Effect of two phenanthrene alkaloids on angiotensin II‐induced leukocyte–endothelial cell interactions in vivo

  2003cites this paper
• Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.

  2003cites this paper
• Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms.

  2002cites this paper
• Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

  2002cites this paper
• Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.

  2002cites this paper
• Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils.

  2002cites this paper
• Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.

  2001cites this paper
• Differential inhibition of equine neutrophil function by phosphodiesterase inhibitors.

  2001cites this paper
• The future of antiinflammatory therapy.

  2001cites this paper
• In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

  2001cites this paper
• Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

  2001cites this paper
• Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.

  2001cites this paper
• Phosphodiesterase 4 Inhibitors and the Treatment of Asthma

  2000cites this paper
• CGS 21680, dibutyryl cyclic AMP and rolipram attenuate the pro-inflammatory interactions of the Pseudomonas aeruginosa -derived pigment, 1-hydroxyphenazine, with human neutrophils.

  2000cites this paper
• Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils

  2000cites this paper
• The effect of selective and non‐selective phosphodiesterase inhibitors on allergen‐ and leukotriene C4‐induced contractions in passively sensitized human airways

  2000cites this paper
• beta-Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils.

  2000cites this paper
• The effect of phosphodiesterase III inhibitors on human neutrophil function

  2000cites this paper
• Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease.

  2000cites this paper
• Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs.

  2000cites this paper
• Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets.

  2000cites this paper
• Theophylline improves functional recovery of isolated rat lungs after hypothermic preservation.

  1999cites this paper
• Activation of p38 Mitogen-activated Protein Kinase by Lipopolysaccharide in Human Neutrophils Requires Nitric Oxide-dependent cGMP Accumulation*

  1999cites this paper
• Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium

  1999cites this paper
• Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity

  1999cites this paper
• Bronchodilator and anti‐inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes

  1999cites this paper
• Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes.

  1999cites this paper
• The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐α and leukotriene B4 in a novel human whole blood assay

  1999cites this paper
• Therapeutic potential of selective PDE inhibitors in asthma.

  1999cites this paper
• Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease

  1999cites this paper
• Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).

  1999cites this paper
• The therapeutic potential of PDE4 inhibitors.

  1999cites this paper
• Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors.

  1998cites this paper
• Differential Regulation of Formyl Peptide and Platelet-activating Factor Receptors

  1998cites this paper
• Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

  1998cites this paper
• New therapies for chronic obstructive pulmonary disease.

  1998cites this paper
• Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III.

  1998cites this paper
• Anti-Oxidative Effects of Theophylline on Human Neutrophils Involve Cyclic Nucleotides and Protein Kinase A

  1998cites this paper
• On the induction of cyclooxygenase-2, inducible nitric oxide synthase and soluble phospholipase A2 in rat mesangial cells by a nonsteroidal anti-inflammatory drug: the role of cyclic AMP.

  1998cites this paper
• Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP‐activated human neutrophils

  1998cites this paper
• Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation

  1998cites this paper
• Effect of PDE4 inhibitors on zymosan‐induced IL‐8 release from human neutrophils: synergism with prostanoids and salbutamol

  1998cites this paper
• Inhibition of histamine release from dispersed canine skin mast cells by cyclosporin A, rolipram and salbutamol, but not by dexamethasone or sodium cromoglycate.

  1998cites this paper
• 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

  1998cites this paper
• Involvement of cyclic AMP generation in the inhibition of respiratory burst by 2-phenyl-4-quinolone (YT-1) in rat neutrophils.

  1998cites this paper
• Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.

  1997cites this paper
• Bronchodilator and anti-inflammatory activities of SCA40: Studies in human isolated bronchus, human eosinophils, and in the guinea-pig in vivo

  1997cites this paper
• In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor‐α release by PDE inhibitors

  1997cites this paper
• Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.

  1997cites this paper
• Cyclic nucleotide-induced migration of electropermeabilized neutrophils: The effect of phosphodiesterase-resistant analogues

  1997cites this paper
• The effect of prostacyclin mimetics on neutrophil function.

  1997cites this paper
• Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes.

  1997cites this paper
• Pharmacological activity of PF-904 in guinea pig in vivo, and on human bronchus and neutrophils in vitro.

  1997cites this paper
• Inhibitory Effects of N‐acetylcysteine on Superoxide Anion Generation in Human Polymorphonuclear Leukocytes

  1997cites this paper
• Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.

  1996cites this paper
• Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim

  1996cites this paper
• The inhibitory effect of prostaglandin E2 on rat neutrophil aggregation

  1996cites this paper
• Constituents of Veltheimia viridifolia; I. Homoisoflavanones of the Bulbs*

  1996cites this paper
• Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxic shock.

  1996cites this paper
• Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.

  1996cites this paper
• Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines.

  1996cites this paper
• The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function.

  1996cites this paper
• Synergistic Inhibition of Human Polymorphonuclear Function by Prostaglandin E1 and Linsidomine

  1996cites this paper
• Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.

  1995cites this paper
• Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability--effect of adenylate cyclase stimulation and phosphodiesterase inhibition.

  1995cites this paper
• Differential effects of non‐selective and selective phosphodiesterase inhibitors on human eosinophil functions

  1995cites this paper